X4 Pharmaceuticals to Join H.C. Wainwright 2nd Annual BioConnect Investor Conference

BOSTON, May 13, 2024-- X4 Pharmaceuticals (Nasdaq: XFOR), an organization dedicated to enhancing the quality of life for individuals facing rare immune system disorders, announced its participation in the forthcoming H.C. Wainwright 2nd Annual BioConnect Investor Conference. This event is scheduled for May 20, 2024, at the Nasdaq Stock Exchange in New York City. The conference will feature a fireside chat, which will begin at 2:00 PM ET and will be accessible via webcast.

X4 Pharmaceuticals is committed to advancing treatments for patients by creating and bringing to market innovative therapies for rare immune system diseases that have significant unmet medical needs. By utilizing their knowledge in CXCR4 and immune system biology, the company has successfully developed mavorixafor, which has been approved in the U.S. under the brand name XOLREMDI™ (mavorixafor) capsules for its initial indication. Additionally, X4 Pharmaceuticals is exploring other potential uses for mavorixafor in various indications.

The company is headquartered in Boston, Massachusetts, with a research center of excellence located in Vienna, Austria. For further information, please visit their official website.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!